Intel’s Stock Sinks As Trump Calls For CEO’s Resignation
The stock of chipmaker Intel (INTC) fell 3% after U.S. President Donald Trump publicly called for the resignation of Chief Executive Officer (CEO) Lip-Bu Tan.
In a social media post, President Trump wrote that Tan is “highly CONFLICTED and must resign, immediately. There is no other solution to this problem.”
The president’s comments come after some lawmakers in Congress questioned Tan’s ties to China and referenced a past criminal case involving Cadence Design Systems (CDNS), where Tan was CEO until 2021.
Tan was named Intel’s CEO in March as the company undertakes a multiyear turnaround strategy aimed at reversing declining sales and lost market share.
In a public statement released after Trump’s social media posts, Intel wrote that it and Tan are “deeply committed to advancing U.S. national and economic security interests.”
Earlier media reports claim that Tan has invested in several Chinese companies, including some linked to the country’s military, both directly and through venture funds.
Since assuming the helm of Intel this spring, Tan has announced several cost cutting measures at Intel.
These have included cuts to the company’s foundry division, which makes microchips for other companies and posted a loss of $3.17 billion U.S. in 2024.
The company has also canceled plans for microchip factories in Germany and Poland and said it would slow construction of a major new factory being built in Ohio.
INTC stock is down 2% on the year and trading at $19.77 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


